Business Context and Reporting Period
This Form 8-K was filed by Neuralstem, Inc. on October 29, 2014, reporting events occurring on October 28, 2014. The filing details a material amendment to an existing loan agreement with Hercules Technology III, L.P. Note: The request metadata references "Palisade Bio, Inc.," but the filing text explicitly identifies the registrant as Neuralstem, Inc.
Key Financial Metrics and Debt Structure
The company executed a Second Amendment to its Loan Agreement, borrowing a total of $10 million. The allocation of these funds was as follows:
- Refinancing: $5,581,292 used to refinance the outstanding balance of the initial loan.
- Transaction Costs: $104,820 used to pay costs and expenses related to the amendment.
- Net Proceeds: $4,313,888 received as additional capital.
Revised Loan Terms:
- Interest Rate: Reduced to the greater of 10.0% or 10.0% plus the prime rate minus 3.25%.
- Maturity Date: Extended to April 1, 2017.
- Repayment Schedule: Interest-only payments from January 1, 2015, to October 1, 2015. Principal and interest amortization over 24 months thereafter, with a balloon payment for any remaining balance at maturity.
- Prepayment Charges: Reduced to 2.50% (first 12 months), 1.50% (months 13-24), and 0.50% (thereafter).
Equity Issuance: The company issued a five-year warrant to Hercules to purchase 75,188 shares of common stock at an exercise price of $2.66 per share.
Material Changes Versus Prior Period
Compared to the original March 2013 Loan Agreement, the Second Amendment significantly altered the capital structure and repayment obligations:
- Debt Load: Increased total borrowing capacity by $10 million, partially refinancing existing debt.
- Cost of Capital: The interest rate was reduced from the prior terms.
- Liquidity Timeline: The maturity date was extended by approximately three years, and a new interest-only period was established to defer principal payments.
- Prepayment Flexibility: Prepayment penalties were lowered across all timeframes.
Outlook, Risks, and Unusual Items
Management Commentary: The filing indicates a strategic move to secure additional capital ($4.3 million net) while reducing the cost of existing debt and extending the repayment horizon. The issuance of the warrant represents a dilutive equity component tied to the debt financing.
Risks and Contingencies:
- Equity Dilution: The warrant issuance is subject to adjustment upon merger events, share reclassifications, or dividends.
- Prepayment Constraints: While reduced, prepayment charges still apply if the company seeks to retire the debt early.
- Regulatory Status: The warrant was issued under Section 4(2) of the Securities Act and Regulation D, meaning it is unregistered.
Financial Metrics: The filing text does not provide clear values for revenue, profit, cash flow, or operating margins. This is a current report focused on a specific transaction rather than a periodic financial statement.
Key Facts for Investor Verification
- Verify the company name discrepancy between the request metadata (Palisade Bio) and the filing (Neuralstem, Inc.).
- Confirm the exact outstanding principal balance post-refinancing and the impact of the $4.3 million net proceeds on the company's cash position.
- Review the full text of the Second Amendment (Exhibit 10.01) and Warrant (Exhibit 4.01) for covenants not summarized in this report.
- Assess the dilution impact of the 75,188 warrant shares at the $2.66 exercise price relative to the current market price.
- Monitor the company's ability to service the interest-only payments starting January 1, 2015, and the subsequent principal amortization.